On Thursday, October 31, a Maryland federal judge denied a bid by Classen Immunotherapies, Inc. to reconsider a 2006 summary judgment granted to Elan Pharmaceuticals, Inc. over two patents related to muscle relaxant Skelaxin®. Finnegan represented Elan in this matter. James B. Monroe, Finnegan counsel to Elan, told Law360 “they are pleased with the result.”
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.